NRX Pharmaceuticals Warrant
NRXPW
NRXPW was delisted on the 22nd of May, 2026.
2 hedge funds and large institutions have $5K invested in NRX Pharmaceuticals Warrant in 2022 Q3 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 2 closing their positions.
25% more capital invested
Capital invested by funds: $4K → $5K (+$1K)
0.03% more ownership
Funds ownership: 0% → 0.03% (+0.03%)
50% less funds holding
Funds holding: 4 → 2 (-2)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
YCM
1
Yakira Capital Management
Westport,
Connecticut
| $5K | – | – | – |
|
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$2K | -15,678 | Closed |
|
NRXPW Hedge Fund Activity: Q3 2022 in Review
2 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in NRX Pharmaceuticals Warrant (NRXPW) for Q3 2022, worth a combined $5K — up 25% from $4K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of NRXPW and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Susquehanna International Group, exiting entirely with an estimated $2K sold.
- 2 institutional investors held NRX Pharmaceuticals Warrant (NRXPW) as of Q3 2022, down from 4 in Q2 2022.
- Funds reported $5K of NRX Pharmaceuticals Warrant stock for Q3 2022, up 25% quarter-over-quarter.
- 0 funds opened new NRX Pharmaceuticals Warrant positions in Q3 2022 and 2 closed out, a net change of -2 holders.
- The largest NRX Pharmaceuticals Warrant seller in Q3 2022 was Susquehanna International Group, an estimated $2K sold.
Based on aggregated 13F filings for Q3 2022.